These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11402087)

  • 1. Practical guidelines for the use of NESP in treating renal anaemia.
    Aljama P; Bommer J; Canaud B; Carrera F; Eckardt KU; Hörl WH; Krediet RT; Locatelli F; Macdougall IC; Wikström B;
    Nephrol Dial Transplant; 2001; 16 Suppl 3():22-8. PubMed ID: 11402087
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC; Matcham J; Gray SJ;
    Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).
    Macdougall IC
    Nephrol Dial Transplant; 2001; 16 Suppl 3():14-21. PubMed ID: 11402086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved haemoglobin concentrations with IV darbepoetin alfa--case studies of haemodialysis patients.
    Thiele A; Wittner M
    Curr Med Res Opin; 2002; 18(7):440-4. PubMed ID: 12487509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
    Nagano N
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
    [No Abstract]   [Full Text] [Related]  

  • 7. [Advances in therapy of renal anemia: darbepoetin alfa].
    Schaefer R
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with darbepoetin-alfa (Aranesp).
    Locatelli F; Del Vecchio L; Marai P
    Contrib Nephrol; 2002; (137):403-7. PubMed ID: 12101985
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis.
    De Palo T; Giordano M; Palumbo F; Bellantuono R; Messina G; Colella V; Caringella AD
    Pediatr Nephrol; 2004 Mar; 19(3):337-40. PubMed ID: 14745634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical potential of novel erythropoiesis stimulating protein.
    Sunder-Plassmann G; Hörl WH
    Expert Opin Biol Ther; 2001 Jul; 1(4):733-9. PubMed ID: 11727508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa: its use in anemia associated with chronic kidney disease.
    Robinson DM; Easthope SE
    BioDrugs; 2005; 19(5):327-43. PubMed ID: 16207074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin in kidney disease and type 2 diabetes.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
    Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Korbet SM
    Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
    [No Abstract]   [Full Text] [Related]  

  • 20. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.